Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.30 |
| ▸ | GANAB | Q14697 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973493 | 0.73 | — | — | |
| SCHEMBL11031394 | 0.71 | TFPI2 (0.31) | — | |
| SCHEMBL9547230 | 0.70 | — | — | |
| SCHEMBL3378196 | 0.64 | GAA (0.30) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL7888503 | 0.64 | GBA1 (0.41) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL7887115 | 0.64 | GBA1 (0.41) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL7893120 | 0.64 | GBA1 (0.41) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL7881588 | 0.64 | GBA1 (0.41) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL9710934 | 0.64 | GBA1 (0.41) | GBA1GAAMEN1CYP1A2CYP2C9 | |
| SCHEMBL9845642 | 0.62 | TRPA1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049678-A2 | TREATMENT OF ENERGY UTILIZATION DISEASES | SUMMIT CORPORATION PLC (GB) | 2010-05-06 | — | — | WO | disclosed |